Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
| Autor: | Bernd Hertenstein, Rudolf Schlag, Nadine Pletsch, Susanne Saußele, Mathias Hänel, Stephan Kremers, Wolf-Karsten Hofmann, Rüdiger Hehlmann, Martin Wernli, Hartmut Link, Martin C. Müller, Stefan W. Krause, Gabriela M. Baerlocher, Annette Schreiber, Elisabeth Lange, Lida Kalmanti, Ulrike Proetel, Dominik Heim, Lothar Müller, Joerg Hasford, Hermann Einsele, Andreas Hochhaus, Michael Lauseker, Markus Pfirrmann, Benjamin Hanfstein |
|---|---|
| Přispěvatelé: | for the German Chronic Myeloid Leukemia Study Group, and the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent 610 Medicine & health Early applied higher imatinib dosages Piperazines law.invention Young Adult Randomized controlled trial law Internal medicine hemic and lymphatic diseases Leukemia Myelogenous Chronic BCR-ABL Positive medicine Older patients Humans ddc:610 Adverse effect Protein Kinase Inhibitors Aged Aged 80 and over Relative survival Dose-Response Relationship Drug business.industry Chronic myeloid leukemia Age Factors Myeloid leukemia Imatinib General Medicine Hematology Different imatinib dose regimens Middle Aged medicine.disease Surgery Leukemia Imatinib mesylate Pyrimidines Treatment Outcome Tolerability Benzamides Imatinib Mesylate Original Article Female business medicine.drug |
| Zdroj: | Annals of Hematology Proetel, Ulrike; Pletsch, Nadine; Lauseker, Michael; Müller, Martin C; Hanfstein, Benjamin; Krause, Stefan W; Kalmanti, Lida; Schreiber, Annette; Heim, Dominik; Baerlocher, Gabriela M.; Hofmann, Wolf-Karsten; Lange, Elisabeth; Einsele, Hermann; Wernli, Martin; Kremers, Stephan; Schlag, Rudolf; Müller, Lothar; Hänel, Mathias; Link, Hartmut; Hertenstein, Bernd; ... (2014). Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of hematology, 93(7), pp. 1167-1176. Springer 10.1007/s00277-014-2041-0 |
| ISSN: | 1432-0584 0939-5555 |
| Popis: | The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (≥65 years vs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink